LAMICTAL (lamotrigine) by GSK is organic cation transporter 2 inhibitors [moa]. Approved for anti-epileptic agent [epc]. First approved in 1994.
Drug data last refreshed 31m ago · AI intelligence enriched 3w ago
LAMICTAL (lamotrigine) is an oral small-molecule anti-epileptic agent approved in 1994 that inhibits organic cation transporters to reduce neuronal hyperexcitability. It is indicated for epilepsy management and has become a widely used treatment across multiple seizure types. The drug is now approaching loss of exclusivity with significant generic competition.
As a mature product approaching LOE with moderate competitive pressure (60/100), the brand team is likely consolidating resources and shifting focus to defending market share against generics rather than expansion.
Organic Cation Transporter 2 Inhibitors
Anti-epileptic Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine
A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults
Worked on LAMICTAL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$112M Medicare spend — this is a commercially significant brand
Working on LAMICTAL offers limited career growth potential given its LOE approaching status and mature market position; roles are primarily defensive (protecting market share, managing generic transition) rather than growth-oriented. Career value is best suited to professionals seeking stability in a legacy product or those gaining experience in market access and generic response strategies.